Jaipur, December 7 – According to the Rajasthan Medical and Health Department, authorities are stepping up their campaign against the production and sale of fake medicines across the state.
Late on Friday night, officials from the Food Safety and Drug Control Directorate carried out a large raid, seizing drugs valued at ₹3.73 crore from a company based in Jaipur, the agency said on Saturday.
Rajasthan Food Safety Commissioner T. Shubhamangala confirmed that the goods came from GK Enterprises, a firm operating in the city.
Drug Controller Ajay Pathak explained that the company was distributing counterfeit and substandard tablets, such as Winset‑L and Algivin‑M, which were mislabeled as being produced by YL Pharma in Baddi, Himachal Pradesh.
During a check, Drug Control Officer (DCO) Komal Rupchandani learned from former partner Giriraj Ajmera that he had left the firm in 2019.
Under the Drugs and Cosmetics Act, 1940, and its 1945 Rules, any change in partnership must be reported and a fresh license filed within three months.
Nevertheless, the remaining partner, Khemchand, reportedly continued to operate without securing the required license.
In light of these findings, DCOs Komal Rupchandani and Ashok Kumar Meena filed a case against Khemchand for running pharmaceutical activities without authorization.
Authorities are pursuing legal action and continuing investigations.
Earlier in late 2025, the state government banned almost 40 specific medicines after they were found to be substandard and stopped the distribution of all 19 products from Kaysons Pharma.
These measures followed quality-control lapses and incidents involving contaminated cough syrups that tragically caused child deaths.
This year, the Rajasthan Medical Services Corporation (RMSC) has black‑listed seven companies and 40 medicines that failed quality checks – a record number since the corporation’s founding, the agency said in November.
State Medical and Health Minister Gajendra Singh Khinvsar highlighted that while maintaining a smooth Free Medicine Scheme is vital, ensuring that only standard-quality drugs reach patients remains the top priority.
He added that strict penalties are being imposed on firms that do not meet quality standards, with seven companies and 40 products banned in 2025 – a new high for the corporation.
arc/khz
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
